Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo

Zhong,Xiaoyong; Lin,Jiumao; Zhou,Jianheng; Xu,Wei; Hong,Zhenfeng

doi:10.3892/mmr.2015.3566

Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo

Authors:
- Xiaoyong Zhong
- Jiumao Lin
- Jianheng Zhou
- Wei Xu
- Zhenfeng Hong
View Affiliations

Affiliations: Department of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China, Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China, Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China, Department of Pharmacology, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China
Published online on: March 27, 2015 https://doi.org/10.3892/mmr.2015.3566
Pages: 1699-1708
Copyright: © Zhong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies by our group showed that Qianliening capsules (QC), a clinically proven effective traditional Chinese formulation that has long been used in the treatment of benign prostatic hyperplasia (BPH), is capable of inhibiting BPH in vivo and in vitro via the promotion of apoptosis, suppression of the EGFR/STAT3 signaling pathway and regulating the expression of sex hormones as well as their receptors. However, the mechanism of its anti‑BPH activity has remained to be fully elucidated. The present study aimed to investigate the mechanism underlying the anti‑proliferative effect of QC in vivo and in vitro. Castrated male Sprage‑Dawley (SD) rats where subcutaneously injected with testosterone propionate and the WPMY‑1 cell line was stimulated with basic fibroblast growth factor in order to generate BPH in vivo and in vitro separately, both of which were then subjected to QC treatment. Finasteride was used as a positive control drug for the in vivo study. In the present study, it was found that treatment with QC or finasteride significantly reduced the prostatic index (PI=prostate wet weight/body weight x 100) in a rat model of BPH (P<0.05). In addition, reverse transcription quantitative polymerase chain reaction (RT‑PCR) and western blot analyses showed that QC or finasteride treatment significantly inhibited model construction‑induced upregulation of expression of proliferating cell nuclear antigen, cyclin D1 and cyclin-dependent kinase 4 in prostatic tissues of rats with BPH (P<0.05). The in vitro study further proved that QC exhibited anti‑proliferative properties via G1/S cell cycle arrest in the WPMY‑1 cell line, as evidenced by colony formation, flow cytometric cell cycle, immunoblot and RT‑PCR analyses. In conclusion, the present study demonstrated that inhibition of cell proliferation via G1/S cell cycle arrest may be one of the underlying mechanisms of the effect of QC on BPH.

View Figures

View References

1	Kirby RS: The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 56(Suppl 5): 3–6. 2000. View Article : Google Scholar : PubMed/NCBI
2	Djavan B: Lower urinary tract symptoms/benign prostatic hyperplasia 1: fast control of the patient’s quality of life. Urology. 62(Suppl 3): 6–14. 2003. View Article : Google Scholar : PubMed/NCBI
3	Lucia MS and Lambert JR: Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 9:272–278. 2008. View Article : Google Scholar : PubMed/NCBI
4	Mori H, Maki M, Oishi K, et al: Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate. 16:71–80. 1990. View Article : Google Scholar : PubMed/NCBI
5	Giri D and Ittmann M: Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 159:139–47. 2001. View Article : Google Scholar : PubMed/NCBI
6	Bartsch G, Brüngger A, Schweikert U, Hintner H, Höpfl R and Rohr HP: Benign prostatic hyperplasia: a stromal disease. Urologe A. 28:321–328. 1989.In German. PubMed/NCBI
7	Djavan B, Remzi M, Erne B and Marberger M: The pathophysiology of benign prostatic hyperplasia. Drugs Today (Barc). 38:867–876. 2002. View Article : Google Scholar
8	Roehrborn CG: Pathology of benign prostatic hyperplasia. Int J Impot Res. 20(Suppl 3): 11–18. 2008. View Article : Google Scholar
9	Zhang MD, Zhao YN and An LW: B-cell lymphoma/leukemia-2 and benign prostatic hyperplasia. Chin J Androl. 15:452–454. 2009.In Chinese.
10	Kyprianou N, Tu H and Jacobs SC: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 27:668–675. 1996. View Article : Google Scholar : PubMed/NCBI
11	Claus S, Berges R, Senge T and Schulze H: Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. J Urol. 158:217–221. 1997. View Article : Google Scholar : PubMed/NCBI
12	Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB and Conti CJ: Expression of G1 cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ. 7:1571–1578. 1996.PubMed/NCBI
13	Graña X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
14	Zhong W, Peng J, He H, et al: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 31:E8–E15. 2008.PubMed/NCBI
15	McVary KT: A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 29:387–398. 2007. View Article : Google Scholar : PubMed/NCBI
16	Schulman CC: Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology. 62(3 Suppl 1): 24–33. 2003. View Article : Google Scholar : PubMed/NCBI
17	Lieber MM: Pharmacologic therapy for prostatism. Mayo Clin Proc. 73:590–596. 1998. View Article : Google Scholar : PubMed/NCBI
18	Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C and Lau J: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. CD0014232000.PubMed/NCBI
19	McPartland JM and Pruitt PL: Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc. 100:89–96. 2000.PubMed/NCBI
20	Peng CC, Liu JH, Chang CH, et al: Action mechanism of Ginkgo biloba Leaf extract intervened by exercise therapy in treatment of benign prostate hyperplasia. Evid Based Complement Alternat Med. 2013:4087342013. View Article : Google Scholar : PubMed/NCBI
21	Hong ZF, Lin JM, Zhong XY, et al: Qianliening capsule inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis. Chin J Integr Med. 18:824–830. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lin J, Zhou J, Xu W, Zhong X, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway. Exp Ther Med. 5:1293–1300. 2013.PubMed/NCBI
23	Zheng H, Xu W, Lin J, Peng J and Hong Z: Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis. Mol Med Rep. 7:848–854. 2013.PubMed/NCBI
24	Zhou J, Lin J, Wei X, Zhong X, Zheng Y, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia through regulating the expression of sex hormones, estrogen receptor and androgen receptor. Afr J Pharm Pharmacol. 6:173–180. 2012. View Article : Google Scholar
25	Xu W, Li H, Lin J, et al: Optimization of the chitosan purification process of Qianleining capsule by orthogonal test. J Zhejiang Univ Trad Chin Med. 35:571–574. 2011.
26	Shin IS, Lee MY, Ha HK, Seo CS and Shin HK: Inhibitory effect of Yukmijihwangtang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med. 12:482012. View Article : Google Scholar
27	Wang Y, Shao JC and Zhang SW: Histomorphological studies on hyperplastic prostate of castrated rat caused by androgen. Zhonghua Nan Ke Xue. 8:190–193. 2002.In Chinese.
28	Wang Y, Shao JC and Zhang SW: Histomorphological studies on hyperplastic prostate of castrated rat caused by androgen. Chin J Androl. 3:190–193. 2002.In Chinese.
29	Nurse P, Masui Y and Hartwell L: Understanding the cell cycle. Nat Med. 4:1103–1106. 1998. View Article : Google Scholar : PubMed/NCBI
30	Morgan DO: Principles of CDK regulation. Nature. 374:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
31	Nurse P: A long twentieth century of the cell cycle and beyond. Cell. 100:71–78. 2000. View Article : Google Scholar : PubMed/NCBI
32	Day PJ, Cleasby A, Tickle IJ, et al: Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA. 106:4166–4170. 2009. View Article : Google Scholar : PubMed/NCBI
33	Sridhar J, Akula N and Pattabiraman N: Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J. 8:E204–221. 2006. View Article : Google Scholar : PubMed/NCBI
34	Park KI, Park HS, Kang SR, et al: Korean Scutellaria baicalensis water extract inhibits cell cycle G1/S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells. J Ethnopharmacol. 133:634–641. 2011. View Article : Google Scholar
35	Bantis A, Giannopoulos A, Gonidi M, et al: Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology. 15:25–31. 2004. View Article : Google Scholar : PubMed/NCBI